Biohaven 302 OCD Research Study

20 Apr Biohaven 302 OCD Research Study

To evaluate the efficacy of troriluzole as adjunctive therapy compared to placebo in subjects with OCD who have had an inadequate response to their current OCD treatment based on the change in their Y-BOCS score
To assess the safety and tolerability of troriluzole, relative to placebo, in subjects with OCD
To evaluate the efficacy of troriluzole compared to placebo on functional disability as measured by the Sheehan Disability Scale (SDS)
To evaluate the efficacy of troriluzole compared to placebo on global clinical condition as measured by the Clinical Global Impression Severity Scale (CGI-S)

This is a Phase 3 study.

Total duration of study is 10 weeks and then a return in 2 weeks after discontinuing medication for follow up safety visit.
This study has an open-label extension for those elgible.

Participant Eligibility

Males and females between the ages of 18 and 65 inclusive
Must have primary diagnosis of OCD
Duration of OCD must be at least 1 year
Subjects must be currently experiencing non-response or inadequate response to their current OSC medication
Subjects should currently be on an SSRI (with exception of fluvoxamine) or clomipramine, venlafaxine, or desvenlafaxine for an adequate duration of at least 8 weeks
Subjects not on above medication can be prescreened at site

Contact

Enroll
(425) 453-0404 x_____